Stay updated with breaking news from Dave Hava. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates - Phenylketonuria program on track for Phase 3 trial initiation in first half of 2023... | March 29, 2023
– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934...
Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU) - read this article along with other careers information, tips and advice on BioSpace
CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology,...